New Brain Cancer Treatment Doubles Survival in Mice

A new drug delivery system doubled survival time for mice with glioblastoma, the most aggressive form of brain cancer in adults.

Researchers at the University of Cincinnati and Johns Hopkins Medicine developed a mesh made of nanofibers that releases three drugs directly at the tumor site. The drugs work better together than alone, creating what scientists call synergism.

"When you add them together, three things can happen," said Andrew Steckl, a distinguished research professor at UC. "The combination is negative, the effect is additive like one plus one equals two, or it's synergistic, which is like one plus one equals three."

The results were striking. All untreated mice died within 19 days. But most mice treated with the three-layer mesh survived twice as long, and 40% lived past the 120-day conclusion of the study.

Glioblastoma kills about 13,000 Americans each year and rarely responds to treatment for long. The cancer's cells constantly mutate to evade drugs. The blood-brain barrier also blocks most chemotherapy from reaching tumors.

"It's tough to control," Steckl said. "It comes in through the window and when you close the window, it comes through the door."

The new system solves both problems. Doctors can implant the mesh directly where they removed the tumor, bypassing the blood-brain barrier. The mesh releases drugs in precise doses over time, with some acting immediately and others providing long-lasting treatment.

Lead author Daewoo Han, an assistant professor at UC, said the mesh can be customized to each patient. Doctors control the exact dosage, release timing, and shape of the implant.

Why This Inspires

Betty Tyler, a neurosurgery professor at Johns Hopkins, has spent her career developing cancer treatments. She said the multi-drug approach represents the future of brain cancer care.

"Current therapies have increased patient survival and given them more birthdays," Tyler said. "But we're still working on improving options."

The delivery system could help treat other difficult cancers beyond glioblastoma. Han and his team are now refining the technology to extend drug release even longer.

The next step is moving toward human trials that could bring this hope to patients facing one of medicine's toughest challenges.